NDA Partners LLC announced today that Dr. Srini Srinivasan, former senior executive at the United States Pharmacopeial Convention (USP), has joined the firm as a Premier Expert consultant. NDA Partners Premier Experts are top tier consultants who design and implement critical solutions to help clients successfully develop new medical products, pursue optimal regulatory pathways, build companies that are attractive to professional investors, and initiate access to global markets.
Rochelle, Virginia (PRWEB) October 12, 2015
Dr. Carl Peck, MD, Chairman of NDA Partners LLC announced today that Dr. Srini Srinivasan, has joined the firm as a Premier Expert consultant. NDA Partners Premier Experts are top tier consultants whose expertise and professional stature enable them to bring extraordinary value to the company's clients. Premier Experts collaborate to design and implement critical solutions to help clients successfully develop their medical products, pursue optimal regulatory pathways, build companies that are attractive to professional investors, and initiate access to global markets.
Dr. Srinivasan is an experienced senior scientist and manager in the areas of drug development and registration, CMC review, drug and dietary supplement GMPs, and foods. His 28 year career at USP was extensive, where he was instrumental in expanding relationships with regulatory agencies in Asia, Africa, and South America as well as the US and EU. He advanced USP’s laboratory operations globally, establishing and managing state-of-the-art analytical laboratories to test chemical and biological medicines, foods, including dietary supplements according to applicable GMPs in India, China, Africa, Brazil and Ghana.
“Dr. Srinivasan’s distinguished career with USP is quite impressive, and his global expertise and in-country experience in important markets such as India and China will bring tremendous value to our clients”, said Dr. Peck.
Dr. Srinivasan’s professional career began at Glaxo in India. He subsequently joined USP in the US where he held many senior executive positions including Executive Vice President and Chief Science Officer, Managing Director for USP India, Head of International Sites, and Vice President of Global Verification Programs. Dr. Srinivasan’s professional accomplishments include establishing the USP Dietary Supplements Verification Programs and leading a Global Body of Experts on the development of public standards with regards to chemical and biological medicines, dietary supplements, and foods.
Dr. Srinivasan received a PhD in Synthetic Organic Chemistry and Natural Products from the University of Western Ontario, Canada, and a MSc in Organic, Physical, and Inorganic Chemistry from Annamalai University, India. In recognition of his leadership roles in the establishment and expansion of its global sites in India China and Brazil, launching USP’s global verification programs for active pharmaceutical ingredients, excipients, and dietary supplements and overall contribution to the public health, USP awarded Dr. Srinivasan an honorary membership in the USP Convention.
About NDA Partners
NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of approximately 60 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.
For the original version on PRWeb visit: http://www.prweb.com/releases/2015/10/prweb12995014.htm